Page last updated: 2024-10-25

cimetidine and Atherosclerotic Parkinsonism

cimetidine has been researched along with Atherosclerotic Parkinsonism in 1 studies

Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Leo, RJ1
Lichter, DG1
Hershey, LA1

Other Studies

1 other study available for cimetidine and Atherosclerotic Parkinsonism

ArticleYear
Parkinsonism associated with fluoxetine and cimetidine: a case report.
    Journal of geriatric psychiatry and neurology, 1995, Volume: 8, Issue:4

    Topics: Aged; Cimetidine; Depressive Disorder; Drug Therapy, Combination; Fluoxetine; Humans; Male; Parkinso

1995